Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET.

The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 30 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

CONTACT: Investor Contact:
Alex Kane
Praxis Precision Medicines
investors@praxismedicines.com
617-300-8481

Media Contact:
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

Staff

Recent Posts

PillSafe Spearheads Solutions to Opioid Crisis With Revolutionary Technology

Government and industry have tried and failed to stem the overdose epidemic for more than…

3 hours ago

The Assistance Fund Opens New Program for Post-Traumatic Stress Disorder

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Post-Traumatic Stress…

3 hours ago

eClinicalWorks EHR Receives HRSA Approval for UDS+ Submissions for Health Centers Nationwide

eClinicalWorks successfully completes UDS+ FHIR® synthetic testing and begins FQHC voluntary testingWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the…

6 hours ago

Health eCareers Publishes 2024 Job Seeker Trends Report

Report Reveals Key Factors Shaping the Healthcare Recruitment and Retention LandscapeNEW YORK, NY / ACCESSWIRE…

6 hours ago

Retired US Marine Colonel Finds Pain Relief with sam(R) Wearable Ultrasound Unit

Sustained acoustic medicine technology from ZetrOZ Systems eliminates veteran's severe knee pain without surgery or…

6 hours ago

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

8 hours ago